Viewray Inc (NASDAQ:VRAY) – Research analysts at Cantor Fitzgerald dropped their FY2017 earnings estimates for shares of Viewray in a research report issued on Sunday. Cantor Fitzgerald analyst C. Bijou now anticipates that the company will post earnings of ($1.08) per share for the year, down from their previous estimate of ($1.03). Cantor Fitzgerald currently has a “Buy” rating and a $13.00 target price on the stock.
VRAY has been the subject of several other research reports. Mizuho restated a “buy” rating and issued a $12.00 price target on shares of Viewray in a research report on Wednesday, October 25th. BidaskClub upgraded shares of Viewray from a “hold” rating to a “buy” rating in a research report on Friday, December 22nd. ValuEngine downgraded shares of Viewray from a “hold” rating to a “sell” rating in a research report on Friday, December 1st. Finally, Northland Securities restated a “buy” rating and issued a $10.00 price target on shares of Viewray in a research report on Friday, November 17th. One analyst has rated the stock with a sell rating, one has issued a hold rating and five have given a buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and an average target price of $11.20.
Viewray (NASDAQ:VRAY) last issued its quarterly earnings results on Monday, November 13th. The company reported ($0.19) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.12) by ($0.07). The company had revenue of $12.20 million for the quarter, compared to analyst estimates of $18.63 million. Viewray’s quarterly revenue was up 2950.0% on a year-over-year basis.
Several large investors have recently modified their holdings of VRAY. Nationwide Fund Advisors increased its stake in Viewray by 843.2% in the 2nd quarter. Nationwide Fund Advisors now owns 16,543 shares of the company’s stock valued at $107,000 after buying an additional 14,789 shares during the period. HighTower Advisors LLC increased its stake in Viewray by 5.0% in the 2nd quarter. HighTower Advisors LLC now owns 21,000 shares of the company’s stock valued at $135,000 after buying an additional 1,000 shares during the period. The Manufacturers Life Insurance Company acquired a new position in Viewray in the 2nd quarter valued at approximately $159,000. Thompson Siegel & Walmsley LLC acquired a new position in Viewray in the 3rd quarter valued at approximately $164,000. Finally, Rhumbline Advisers acquired a new position in Viewray in the 2nd quarter valued at approximately $193,000. Institutional investors and hedge funds own 50.52% of the company’s stock.
ILLEGAL ACTIVITY NOTICE: “FY2017 Earnings Estimate for Viewray Inc (VRAY) Issued By Cantor Fitzgerald” was published by American Banking News and is the property of of American Banking News. If you are accessing this article on another website, it was illegally copied and republished in violation of United States and international trademark and copyright law. The correct version of this article can be accessed at https://www.americanbankingnews.com/2018/01/31/fy2017-earnings-estimate-for-viewray-inc-vray-issued-by-cantor-fitzgerald.html.
Viewray Company Profile
ViewRay, Inc designs, manufactures and markets MRIdian, the magnetic resonance imaging (MRI)-guided radiation therapy system to image and treat cancer patients simultaneously. The Company offers radiation therapy technology combined with magnetic resonance imaging. MRIdian integrates MRI technology, radiation delivery and the Company’s software to locate, target and track the position and shape of soft-tissue tumors while radiation is delivered.
Receive News & Ratings for Viewray Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Viewray and related companies with MarketBeat.com's FREE daily email newsletter.